Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Phase of Trial: Phase III
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Elagolix (Primary)
- Indications Uterine leiomyoma
- Focus Therapeutic Use
- Sponsors AbbVie
- 23 Feb 2017 Planned End Date changed from 1 Jan 2019 to 1 Jul 2019.
- 04 Oct 2016 Status changed from planning to recruiting.
- 18 Sep 2015 New trial record